Efficacy
The efficacy of Kisqali has been investigated in various studies. The following pictures summarize all the main data’s from the MONALEESA 2, 3, 7 studiesTwitter Linkedin Facebook Pinterest Google plusEfficacy
Immune (primary) thrombocytopenia (ITP) studies 1Two phase III, randomised, double-blind, placebo-controlled studies RAISE (TRA102537) and TRA100773B and two open-label studies REPEAT (TRA108057) and EXTEND (TRA105325)...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
As with every medicine, when using REVOLADE, side effects can occur. In the case of serious side effects, it is possible that a dose adjustment is necessary. See also the Summary of Product Characteristics for a full overview of the side effects and...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action
TPO is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand for the TPO-R. Revolade interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades similar but...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources
Patient information leaflet RevoladeThe patient information leaflet for REVOLADE contains important information about its use and possible side effects.
Twitter Linkedin Facebook Pinterest Google plusDosing / Administration
Posology 1Revolade dosing requirements must be individualised based on the patient's platelet counts. The lowest dose of eltrombopag to achieve and maintain a platelet count ≥50,000/µl should be used,...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
As with every medicine, when using Kisqali, side effects can occur. In the case of serious or unacceptable side effects, it is possible that a dose adjustment is necessary. Here you can read more about the side effects of Kisqali. The Majority of AEs...Twitter Linkedin Facebook Pinterest Google plusAdministration
4 week dosing schedule 1 INITIAL DOSING: 600 mg/day (3 tablets of 200 mg) KISQALI in combination with a NSAI Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for...Twitter Linkedin Facebook Pinterest Google plusReimbursement
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...
Twitter Linkedin Facebook Pinterest Google plus